Table 2.
Multiple linear regression analysis for the association of FMD and AIx with several variables
| Variables | Regression analysis for the association of FMD (dependent variable) with Lp-PLA2 after adjustment for multiple classical risk factors for CAD | Regression analysis for the association of AIx (dependent variable) with Lp-PLA2 after adjustment for multiple classical risk factors for CAD | ||||
|---|---|---|---|---|---|---|
| b coefficient | 95% CI | P value | b coefficient | 95% CI | p-value | |
| Gender | − 0.30 | − 1.48 – 0.87 | 0.61 | −7.16 | − 11.30 – 3.03 | < 0.001 |
| Age (years) | − 0.01 | − 0.04 – 0.03 | 0.69 | 0.22 | 0.11 – − 0.34 | < 0.001 |
| Duration of CAD (months) | 0.01 | − 0.01 – 0.02 | 0.59 | 0.01 | −0.05 – 0.07 | 0.68 |
| Arterial hypertension | 0.76 | −0.18 – 1.69 | 0.11 | −0.94 | −4.12 – 2.25 | 0.56 |
| Diabetes mellitus | −0.25 | −2.07 – 1.57 | 0.79 | 5.89 | 0.01–11.78 | 0.05 |
| Hyperlipidemia | −0.20 | −1.10 – 0.70 | 0.66 | 1.43 | −1.74 – 4.59 | 0.37 |
| Smoking history | −0.18 | −0.64 - 0.28 | 0.44 | 1.66 | 0.07–3.25 | 0.04 |
| Family history for CAD | 0.74 | −0.07 – 1.55 | 0.07 | −1.26 | −4.12 – 1.60 | 0.39 |
| Previous MI | 0.08 | −0.60 – 0.77 | 0.81 | 0.07 | −2.40 – 2.53 | 0.96 |
| Statins | −1.12 | −2.32 – 0.08 | 0.07 | −1.98 | −5.96 – 1.99 | 0.33 |
| Antidiabetic agents | −0.01 | −1.80 – 1.78 | 0.99 | −5.49 | −11.31 – 0.33 | 0.06 |
| ACEi/ARBs | −0.18 | −0.94 – 0.57 | 0.63 | 1.61 | −1.13 – 4.35 | 0.25 |
| β-blockers | 0.04 | −0.72 – 0.81 | 0.91 | 0.29 | −2.46 – 3.04 | 0.83 |
| Cholesterol (mg/dL) | 0.01 | −0.001 – 0.02 | 0.55 | 0.01 | −0.04 – 0.06 | 0.66 |
| LDL (mg/dL) | −0.01 | −0.03 – 0.01 | 0.19 | 0.02 | −0.04 – 0.08 | 0.50 |
| Glucose (mg/dL) | 0.01 | −0.01 – 0.01 | 0.73 | −0.01 | −0.04 – 0,02 | 0.54 |
| Lp-PLA2 > 138 μg/L | − 0.45 | −0.79 - -0.11 | 0.01 | 1.81 | 0.57 - 3.05 | < 0.001 |
For categorical variables, reference category was set the absence of male gender, diabetes mellitus, hyperlipidemia, smoking history, arterial hypertension, family history for CAD, previous myocardial infarction, statin therapy, treatment with ACEi/ARBs, antidiabetic agents or with β-blockers and Lp-PLA2 < 101 μg/L (1st tertile). AIx Augmentation Index, FMD Flow-mediated dilatation, CAD Coronary artery disease, Lp-PLA2 Lipoprotein-associated phospholipase A2, ACEi Angiotensin converting enzyme inhibitors, ARBs Angiotensin II receptor blockers, MI Myocardial infarction